Influence of treatment with alendronate on the speed of sound, an ultrasound parameter, of the calcaneus in postmenopausal japanese women with osteoporosis

A clinical practice-based observational study

Jun Iwamoto, Tetsuya Takada, Yoshihiro Sato, Hideo Matsumoto

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: The influence of alendronate (ALN) treatment on the quantitative ultrasound parameters of the calcaneus remains to be established in Japanese patients. The aim of the present clinical practice-based observational study was to examine the influence of ALN treatment for 1 year on the speed of sound (SOS) of the calcaneus and bone turnover markers in postmenopausal Japanese women with osteoporosis. Patients and methods: Forty-five postmenopausal Japanese women with osteoporosis who had received treatment with ALN for more than 1 year were enrolled in the study. The SOS and bone turnover markers were monitored over 1 year of ALN treatment. Results: The urinary levels of cross-linked N-terminal telopeptides of type I collagen and serum levels of alkaline phosphatase decreased significantly from the baseline values (-44.9% at 3 months and -22.2% at 12 months, respectively). The SOS increased modestly, but significantly, from the baseline value (0.6% at both 6 and 12 months). The percentage decrease in the urinary levels of cross-linked N-terminal telopeptides of type I collagen at 3 months was significantly correlated with the percentage increase in the SOS only at 6 months (correlation coefficient, 0.299). Conclusion: The present study confirmed that ALN treatment suppressed bone turnover, producing a clinically significant increase in the SOS of the calcaneus in postmenopausal Japanese women with osteoporosis.

Original languageEnglish
Pages (from-to)287-293
Number of pages7
JournalTherapeutics and Clinical Risk Management
Volume8
DOIs
Publication statusPublished - 2012

Fingerprint

Alendronate
Calcaneus
bone disease
Acoustic wave velocity
Osteoporosis
Observational Studies
Ultrasonics
Bone Remodeling
turnover
Bone
Collagen
Therapeutics
Phosphatases
Alkaline Phosphatase
Values
present
Serum

Keywords

  • Biochemical markers
  • Bone turnover
  • Postmenopausal osteoporosis
  • Quantitative ultrasound (QUS)
  • SOS

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research
  • Chemical Health and Safety

Cite this

@article{f72432a32ebc40d5874922fa1643e42e,
title = "Influence of treatment with alendronate on the speed of sound, an ultrasound parameter, of the calcaneus in postmenopausal japanese women with osteoporosis: A clinical practice-based observational study",
abstract = "Purpose: The influence of alendronate (ALN) treatment on the quantitative ultrasound parameters of the calcaneus remains to be established in Japanese patients. The aim of the present clinical practice-based observational study was to examine the influence of ALN treatment for 1 year on the speed of sound (SOS) of the calcaneus and bone turnover markers in postmenopausal Japanese women with osteoporosis. Patients and methods: Forty-five postmenopausal Japanese women with osteoporosis who had received treatment with ALN for more than 1 year were enrolled in the study. The SOS and bone turnover markers were monitored over 1 year of ALN treatment. Results: The urinary levels of cross-linked N-terminal telopeptides of type I collagen and serum levels of alkaline phosphatase decreased significantly from the baseline values (-44.9{\%} at 3 months and -22.2{\%} at 12 months, respectively). The SOS increased modestly, but significantly, from the baseline value (0.6{\%} at both 6 and 12 months). The percentage decrease in the urinary levels of cross-linked N-terminal telopeptides of type I collagen at 3 months was significantly correlated with the percentage increase in the SOS only at 6 months (correlation coefficient, 0.299). Conclusion: The present study confirmed that ALN treatment suppressed bone turnover, producing a clinically significant increase in the SOS of the calcaneus in postmenopausal Japanese women with osteoporosis.",
keywords = "Biochemical markers, Bone turnover, Postmenopausal osteoporosis, Quantitative ultrasound (QUS), SOS",
author = "Jun Iwamoto and Tetsuya Takada and Yoshihiro Sato and Hideo Matsumoto",
year = "2012",
doi = "10.2147/TCRM.S32794",
language = "English",
volume = "8",
pages = "287--293",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Influence of treatment with alendronate on the speed of sound, an ultrasound parameter, of the calcaneus in postmenopausal japanese women with osteoporosis

T2 - A clinical practice-based observational study

AU - Iwamoto, Jun

AU - Takada, Tetsuya

AU - Sato, Yoshihiro

AU - Matsumoto, Hideo

PY - 2012

Y1 - 2012

N2 - Purpose: The influence of alendronate (ALN) treatment on the quantitative ultrasound parameters of the calcaneus remains to be established in Japanese patients. The aim of the present clinical practice-based observational study was to examine the influence of ALN treatment for 1 year on the speed of sound (SOS) of the calcaneus and bone turnover markers in postmenopausal Japanese women with osteoporosis. Patients and methods: Forty-five postmenopausal Japanese women with osteoporosis who had received treatment with ALN for more than 1 year were enrolled in the study. The SOS and bone turnover markers were monitored over 1 year of ALN treatment. Results: The urinary levels of cross-linked N-terminal telopeptides of type I collagen and serum levels of alkaline phosphatase decreased significantly from the baseline values (-44.9% at 3 months and -22.2% at 12 months, respectively). The SOS increased modestly, but significantly, from the baseline value (0.6% at both 6 and 12 months). The percentage decrease in the urinary levels of cross-linked N-terminal telopeptides of type I collagen at 3 months was significantly correlated with the percentage increase in the SOS only at 6 months (correlation coefficient, 0.299). Conclusion: The present study confirmed that ALN treatment suppressed bone turnover, producing a clinically significant increase in the SOS of the calcaneus in postmenopausal Japanese women with osteoporosis.

AB - Purpose: The influence of alendronate (ALN) treatment on the quantitative ultrasound parameters of the calcaneus remains to be established in Japanese patients. The aim of the present clinical practice-based observational study was to examine the influence of ALN treatment for 1 year on the speed of sound (SOS) of the calcaneus and bone turnover markers in postmenopausal Japanese women with osteoporosis. Patients and methods: Forty-five postmenopausal Japanese women with osteoporosis who had received treatment with ALN for more than 1 year were enrolled in the study. The SOS and bone turnover markers were monitored over 1 year of ALN treatment. Results: The urinary levels of cross-linked N-terminal telopeptides of type I collagen and serum levels of alkaline phosphatase decreased significantly from the baseline values (-44.9% at 3 months and -22.2% at 12 months, respectively). The SOS increased modestly, but significantly, from the baseline value (0.6% at both 6 and 12 months). The percentage decrease in the urinary levels of cross-linked N-terminal telopeptides of type I collagen at 3 months was significantly correlated with the percentage increase in the SOS only at 6 months (correlation coefficient, 0.299). Conclusion: The present study confirmed that ALN treatment suppressed bone turnover, producing a clinically significant increase in the SOS of the calcaneus in postmenopausal Japanese women with osteoporosis.

KW - Biochemical markers

KW - Bone turnover

KW - Postmenopausal osteoporosis

KW - Quantitative ultrasound (QUS)

KW - SOS

UR - http://www.scopus.com/inward/record.url?scp=84875280627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875280627&partnerID=8YFLogxK

U2 - 10.2147/TCRM.S32794

DO - 10.2147/TCRM.S32794

M3 - Article

VL - 8

SP - 287

EP - 293

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

ER -